Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) Return on Capital Employed (2016 - 2025)

IGC Pharma has reported Return on Capital Employed over the past 15 years, most recently at 110.44% for Q3 2025.

  • Quarterly Return on Capital Employed fell 8106.0% to 110.44% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 110.44% through Sep 2025, down 8106.0% year-over-year, with the annual reading at 105.36% for FY2025, 8098.0% down from the prior year.
  • Return on Capital Employed was 110.44% for Q3 2025 at IGC Pharma, down from 105.06% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 8.77% in Q3 2022 and troughed at 111.88% in Q1 2025.
  • The 5-year median for Return on Capital Employed is 36.29% (2021), against an average of 49.7%.
  • Year-over-year, Return on Capital Employed plummeted -8853bps in 2023 and then surged 8158bps in 2024.
  • A 5-year view of Return on Capital Employed shows it stood at 37.46% in 2021, then soared by 76bps to 9.13% in 2022, then crashed by -970bps to 97.66% in 2023, then soared by 84bps to 16.08% in 2024, then tumbled by -587bps to 110.44% in 2025.
  • Per Business Quant, the three most recent readings for IGC's Return on Capital Employed are 110.44% (Q3 2025), 105.06% (Q2 2025), and 111.88% (Q1 2025).